Last reviewed · How we verify
LV232
At a glance
| Generic name | LV232 |
|---|---|
| Also known as | LV232 20mg, LV232 60mg |
| Sponsor | Vigonvita Life Sciences |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers (PHASE1)
- Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules (PHASE1)
- A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET (PHASE1)
- Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LV232 CI brief — competitive landscape report
- LV232 updates RSS · CI watch RSS
- Vigonvita Life Sciences portfolio CI